SCHEMBL4010178

SCHEMBL4010178

O=C(Nc1ccccc1)c1n[nH]c2ccc(OS(=O)(=O)c3ccc(Cl)c(Cl)c3)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 6/20 0.51
▸ CDK2 P24941 4/20 0.51
▸ CCNA2 P20248 1/20 0.51
▸ CCNA1 P78396 1/20 0.51
▸ CSNK2A1 P68400 4/20 0.49
▸ PRKAA1 Q13131 2/20 0.48
▸ DYRK3 O43781 1/20 0.48
▸ MAP4K4 O95819 1/20 0.48
▸ CDK1 P06493 1/20 0.48
▸ MARK3 P27448 1/20 0.48
▸ CLK2 P49760 1/20 0.48
▸ GSK3B P49841 1/20 0.48
▸ CSNK1G2 P78368 1/20 0.48
▸ CDK5 Q00535 1/20 0.48
▸ MAP4K2 Q12851 1/20 0.48
▸ CAMK2B Q13554 1/20 0.48
▸ CAMK2G Q13555 1/20 0.48
▸ CAMK2D Q13557 1/20 0.48
▸ DYRK1A Q13627 1/20 0.48
▸ NTRK3 Q16288 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4014969 0.96 FLT3 (0.51) FLT3CDK2CCNA2CCNA1CSNK2A1
SCHEMBL4005400 0.86 APEX1 (0.46) CSNK2A1PRKAA1GSK3BDYRK1AROCK1
SCHEMBL4006597 0.85 CSNK2A1 (0.52) FLT3CDK2CCNA2CCNA1CSNK2A1
SCHEMBL4003421 0.83 CDK7 (0.48) FLT3CDK2CSNK2A1PRKAA1MAP4K4
SCHEMBL4013301 0.83 FLT3 (0.51) FLT3CDK2CCNA2CCNA1CSNK2A1
SCHEMBL4008113 0.83 APEX1 (0.49) CSNK2A1PRKAA1JAK2JAK1PRKAB2
SCHEMBL4008121 0.82 GPR27 (0.55) FLT3CDK2CCNA2CCNA1CSNK2A1
SCHEMBL4008006 0.82 YTHDC1 (0.45) CSNK2A1PRKAA1DYRK1APRKAB2PRKAG1
SCHEMBL4009831 0.81 CSNK2A1 (0.54) FLT3CDK2CCNA2CCNA1CSNK2A1
SCHEMBL4003366 0.80 GPR27 (0.55) FLT3CDK2CCNA2CCNA1CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 — — US disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 — — US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 — — US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 FLT3 58/4885CDK2 10/4885CCNA2 633/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 FLT3 75/4885CDK2 28/4885CCNA2 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback